CB12 is a powerful, unique and patented mouth rinse that ensures not only first class breath, but also provides a daily shot of confidence. Every day and all day CB12 provides 12 hours of protection.
EndWarts is an effective treatment for self-removal of warts on hands, feet and the body.
Dymista is a new nasal spray for the treatment of allergic rhinitis. Dymista is a novel formulation of Azelastine and fluticasone propionate.
Zyclara is an immune response modulator agent, Imiquimod 3,75%, for the treatment of large areas of actinic keratosis.
Elidel is a steroid free drug, Pimecrolimus, for the treatment of atopic dermatitis, which is a chronic recurring inflammatory skin disease.
This website is intended for people seeking information on Meda AB's Global operations. We also have national marketing sites. Links to these are under Meda Worldwide at the top of the page.
Access to the information and documents on this section of Meda’s website may, due to laws and regulations, not be disclosed to certain persons and, accordingly, persons who seek access to this information must inform themselves of, and act in accordance with, any such restrictions. You are asked to review the following information and make the following confirmation each time you seek access to this section of the website. Your confirmation must be truthful.
This material is not directed to, and is not accessible by, persons resident or located in Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or the United States, or in any other jurisdiction where participation in Meda’s new share issue and the purchase or sale or subscription rights, new shares or paid subscribed shares is not permitted.
No action has been, or will be taken, by Meda to permit a public offering in any jurisdiction other than Sweden, Denmark and the United Kingdom. Neither the subscription rights, the BTAs nor the new shares (the “Securities”) have been, or will be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”). The Securities may not be offered or sold, directly or indirectly, in or into the United States or to investors domiciled there, except pursuant to an available exemption from the registration requirements of the Securities Act. The offer is not offered to persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or to persons whose participation in the offer would require additional prospectuses, registrations or other actions in addition to those required under Swedish, Danish or English law. In member states within the European Economic Area (EEA), other than Sweden, Denmark and the United Kingdom, which have implemented Directive 2003/71/EC (the “Prospectus Directive”), an offer of Securities can only be made under an exemption under the Prospectus Directive. Accordingly, the prospectus, application form and other documentation relating to the new issue of shares must not be distributed in any country or jurisdiction where the distribution or the offer requires such measures or would conflict with regulations in such jurisdiction. Violation of the restrictions may be a criminal offence under securities laws or regulations.
By accepting below I confirm that I have read and agree to be bound by the information, instructions, conditions and terms of this website and that I am not located in Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or the United States, or any other jurisdiction in which the distribution or participation of the offer would not be made in compliance with laws and regulations in such jurisdiction or where the participation of the offer requires additional prospectuses, registration or other measures than those required under Swedish, Danish or English law.